App-Quantinova.ai

An interactive web interface for the molecular classification of colorectal cancer from RNA-sequencing data

Gerard Quinn - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism

Kristen Hurov - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Urelumab

Characterisation of co-expression of CD39 with other IO-relevant markers on major T/NK cell TIL subsets

Jim Hair - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Adenosine

A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors

Dionysis Papadatos-Pastos - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

guadecitabine

A survey of EphA2 expression by immunohistochemistry (IHC) in tumor tissue microarrays (TMAs) to support BT5528 indication selection

Carly T. Campbell - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Long-term live imaging of ovarian cancer invasion using optical coherence tomography

Amelia Hallas-Potts - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

N/A

Mass-spectrometry analysis of metastatic matrisome from MC38 experimental liver metastasis

Arseniy E. Yuzhalin - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal liver metastases

N/A

ctDNA detection in early stage non-small cell lung cancer

Katrin Heider - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study

Ryan Hartmaier - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Savolitinib

Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

Pablo Morentin Gutierrez - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC)

David Planchard - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Durvalumab

Indications for systematic prostate biopsy in men with negative multi-parametric magnetic resonance imaging

Chidi N. Molokwu - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Pegylated arginine deiminase sensitizes ASS1-negative and KRAS mutant non-small cell lung cancer to PD-1 blockade immunotherapy

Iuliia Pavlyk - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Atezolizumab

A novel mechanism inducing centrosome amplification in tumor cells

Karuna Mittal - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Utilizing stimulated Raman scattering microscopy to study intracellular distribution of label-free ponatinib in live cells

Kristel Sepp - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

chloroquine

Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

Anna Staniszewska - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon

Diffusion weighted MRI evaluation of response to immunotherapy and radiotherapy in CT26 and 4T1 syngeneic mouse models of cancer

Grazyna Lipowska-Bhalla - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

James William Thomas Yates - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ataxia telangiectasia

Durvalumab

Using a pharmacodynamic biomarker led approach to explore and quantify the combination effect of savolitinib and osimertinib in the LG1208 NSCLC PDX model

Rhys Jones - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Savolitinib

Are circulating microRNAs (miRNAs) ready for inclusion as biomarkers in breast cancer clinical trials

Edward B. Amankwatia - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

miR-16

Filters

45280 Abstracts